Thoracic cancer · 2026
Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Dong Hyun, Hong Min Hee, Jung Hyun Ae, Kim Tae Min, Kim Chang Gon, Ahn Hee Kyung, Lee Youngjoo, Kim Yu Jung, Kim Miso, Youk Jeonghwan, Sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Kim Dong-Wan, Ahn Myung-Ju, Choi Yoon Ji, Lim Sun Min, Kang Jin Hyoung, Keam Bhumsuk, Kim Hye Ryun
Аннотация
BACKGROUND: Central nervous system (CNS) involvement remains a major cause of mortality in patients with epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC), particularly, after progression on EGFR tyrosine kinase inhibitors (TKIs). This pooled analysis evaluated the efficacy of lazertinib in patients with EGFR-mutated NSCLC and CNS involvement, using data from two Phase II trials.
PATIENTS AND METHODS: Patients with EGFR-mutated NSCLC and CNS involvement following prior EGFR TKI therapy enrolled in the KCSG-LU20-15 and KCSG-LU21-01 were included. Overall and intracranial objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) were assessed.
RESULTS: Seventy-two patients were included. The median age was 63 years and 45 patients (62.5%) had leptomeningeal metastases (LM). T790M status was positive in 7 patients, negative in 44, and unknown in 21. Intracranial tumor responses were evaluable in 46 patients; the intracranial ORR was 50.0%, and the intracranial DCR was 97.8%. The median intracranial PFS was 15.2 months. Among 66 patients evaluable for systemic response, the overall ORR and DCR were 22.7% and 97.0%, respectively. The median PFS and overall survival were 10.6 and 17.8 months, respectively. Patients with LM experienced inferior OS and intracranial PFS compared with those without LM. No significant differences in clinical outcomes were observed according to T790M status.
CONCLUSION: Lazertinib demonstrated meaningful CNS activity in patients with EGFR-mutated NSCLC and CNS involvement after prior EGFR TKI exposure, including those with LM. Notably, this activity was observed in a cohort with a low prevalence of confirmed T790M positivity.
PATIENTS AND METHODS: Patients with EGFR-mutated NSCLC and CNS involvement following prior EGFR TKI therapy enrolled in the KCSG-LU20-15 and KCSG-LU21-01 were included. Overall and intracranial objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) were assessed.
RESULTS: Seventy-two patients were included. The median age was 63 years and 45 patients (62.5%) had leptomeningeal metastases (LM). T790M status was positive in 7 patients, negative in 44, and unknown in 21. Intracranial tumor responses were evaluable in 46 patients; the intracranial ORR was 50.0%, and the intracranial DCR was 97.8%. The median intracranial PFS was 15.2 months. Among 66 patients evaluable for systemic response, the overall ORR and DCR were 22.7% and 97.0%, respectively. The median PFS and overall survival were 10.6 and 17.8 months, respectively. Patients with LM experienced inferior OS and intracranial PFS compared with those without LM. No significant differences in clinical outcomes were observed according to T790M status.
CONCLUSION: Lazertinib demonstrated meaningful CNS activity in patients with EGFR-mutated NSCLC and CNS involvement after prior EGFR TKI exposure, including those with LM. Notably, this activity was observed in a cohort with a low prevalence of confirmed T790M positivity.